Guilherme Rabinowits, MD

Cancer Focus:
Head and Neck Cancer, Oral Cavity or Throat Cancer, Skin Cancer (Nonmelanoma), Throat Cancer, Thyroid Cancer, Tongue Cancer

Dr. Guilherme Rabinowits is a Senior Member in the Department of Head and Neck-Endocrine Oncology. Dr. Rabinowits received his MD degree from Fundacao Tecnico-Educacional Souza Marques, Rio de Janeiro, Brazil. He completed an Internal Medicine residency at Lahey Clinic and Medical Center, Burlington, Massachusetts, followed by a Hematology/Medical Oncology Fellowship at the University of Louisville, Kentucky, where he also served as Chief Fellow. He then joined Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, as a Head and Neck Medical Oncologist until his move to Miami. Dr. Rabinowits joins us from the Miami Cancer Institute, Department of Hematology/Medical Oncology. Dr. Rabinowits’s clinical interests focus on head and neck, endocrine, and skin cancers. In addition, he has extensive experience in clinical and translational research in developing novel therapies and clinically impactful biomarkers.

Clinical Trial 23229
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Condition: Multiple
Intervention: Lenti-HPV-07 ()
Status: Open

Clinical Trial 23298
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment Of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda); Placebo (); Zanzalintinib ()
Status: OPEN (SUSPENDED)

Clinical Trial 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()
Status: OPEN (SUSPENDED)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Park SJ, Ellison DM, Weight R, Homsi J, Rabinowits G, Ruiz ES, Strasswimmer J, Simmons J, Panella T, Quek RG, Pouliot JF, Khushalani NI. CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. Future Oncol. 2025 Feb.21(4):431-436. Pubmedid: 39797702. Pmcid: PMC11812358.
• Gonzalez L, Rubens M, Yarlagadda S, Rabinowits G, Kalman NS. Hypofractionated versus standard fractionation radiotherapy for merkel cell carcinoma. Radiat Oncol. 2024 Oct.19(1):142. Pubmedid: 39394124. Pmcid: PMC11468079.
• Goetz JW, Rabinowits G, Kalman N, Villa A. A Review of Immunotherapy for Head and Neck Cancer. J Dent Res. 2024 Nov.103(12):1185-1196. Pubmedid: 39370694. Pmcid: PMC11653306.
• Manoharan M, Kalman NS, Rabinowits G. Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up. Oncologist. 2024 Mar.29(3):192-199. Pubmedid: 37995312. Pmcid: PMC10911926.
• Salz T, Chimonas S, Jinna S, Brens J, Kriplani A, Salner A, Rabinowits G, Currier B, Daly B, Korenstein D. Pain management for post-treatment survivors of complex cancers: a qualitative study of opioids and cannabis. Pain Manag. 2024 Feb.14(2):87-99. Pubmedid: 38318666. Pmcid: PMC10918509.
• Hamid O, Lewis KD, Weise A, McKean M, Papadopoulos KP, Crown J, Kim TM, Lee DH, Thomas SS, Mehnert J, Kaczmar J, Lakhani NJ, Kim KB, Middleton MR, Rabinowits G, Spira AI, Yushak M, Mehmi I, Fang F, Chen S, Mani J, Jankovic V, Wang F, Fiaschi N, Brennan L, Paccaly A, Masinde S, Salvati M, Fury MG, Kroog G, Lowy I, Gullo G. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. J Clin Oncol. 2024 Aug.42(24):2928-2938. Pubmedid: 38900987. Pmcid: PMC11328921.
• Kutuk T, McAllister NC, Rzepczynski AE, Williams A, Young G, Crawley MB, Rabinowits G, Kaiser A, Contreras JA, Kalman NS. Submandibular gland transfer for the prevention of radiation-induced xerostomia in oropharyngeal cancer: Dosimetric impact in the intensity modulated radiotherapy era. Head Neck. 2022 May.44(5):1213-1222. Pubmedid: 35243719.
• Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35902131. Pmcid: PMC9341183.
• Liu KX, Milligan MG, Schoenfeld JD, Tishler RB, Ng AK, Devlin PM, Fite E, Rabinowits G, Hanna GJ, Silk AW, Yoon CH, Thakuria M, Margalit DN. Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 Aug.173:32-40. Pubmedid: 35595174.
• Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 Oct.27(19):5236-5247. Pubmedid: 34301750. Pmcid: PMC9401461.
• Rabinowits G, Migden MR, Schlesinger TE, Ferris RL, Freeman M, Guild V, Koyfman S, Pavlick AC, Swanson N, Wolf GT, Dinehart SM. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innov. 2021 Dec.1(4):100045. Pubmedid: 34909742. Pmcid: PMC8659794.
• Kotecha R, Tonse R, Appel H, Odia Y, Kotecha RR, Rabinowits G, Mehta MP. Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. Curr Oncol. 2021 Apr.28(2):1537-1543. Pubmedid: 33919580. Pmcid: PMC8167720.
• Starrett GJ, Thakuria M, Chen T, Marcelus C, Cheng J, Nomburg J, Thorner AR, Slevin MK, Powers W, Burns RT, Perry C, Piris A, Kuo FC, Rabinowits G, Giobbie-Hurder A, MacConaill LE, DeCaprio JA. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. Genome Med. 2020 Mar.12(1):30. Pubmedid: 32188490. Pmcid: PMC7081548.
• Hanna GJ, Kacew AJ, Tanguturi AR, Grote HJ, Vergara V, Brunkhorst B, Rabinowits G, Thakuria M, LeBoeuf NR, Ihling C, DeCaprio JA, Lorch JH. Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. Front Med (Lausanne). 2020 Jun.7:198. Pubmedid: 32582722. Pmcid: PMC7291775.
• Migden MR, Chandra S, Rabinowits G, Chen CI, Desai J, Seluzhytsky A, Sasane M, Campanelli B, Chen Z, Freeman ML, Ibrahim SF, Khushalani NI, Andria M, Ruiz E. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb.16(4):11-19. Pubmedid: 31951149.
• Harris EJ, Huang J, Carroll E, Lowe AC, Chau NG, Rabinowits G, Haddad R, Hanna GJ, Haddad T, Sanborn M, Kacew A, Lorch J. Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec.5(6):1063-1069. Pubmedid: 33364395. Pmcid: PMC7752061.
• Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 Sep.105(1):132-139. Pubmedid: 31082494.
• Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 May.113:1-9. Pubmedid: 30954880.
• Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 Mar.30(3):471-477. Pubmedid: 30596812. Pmcid: PMC7360148.
• Arbab M, Margalit DN, Tishler RB, Rabinowits G, Pashtan IM, Borgelt BB, Powlis W, Holdsworth CH, Warren LE, Schoenfeld JD. Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head Neck. 2019 Jul.41(7):2111-2115. Pubmedid: 30697925.
• Harris EJ, Hanna GJ, Chau N, Rabinowits G, Haddad R, Margalit DN, Schoenfeld J, Tishler RB, Barletta JA, Nehs M, Janne P, Huang J, Groden P, Kacew A, Lorch J. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019 Feb.9:106. Pubmedid: 30863722. Pmcid: PMC6399130.
• LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB. IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 Apr.41(4):959-966. Pubmedid: 30620435.
• Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 Sep.102(1):137-145. Pubmedid: 29960819.
• D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018 Sep.4(9):e180077. Pubmedid: 29566106. Pmcid: PMC5885245.
• Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul.379(4):341-351. Pubmedid: 29863979.
• Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist. 2018 Jul.23(7):814-821. Pubmedid: 29445030. Pmcid: PMC6058327.
• Rabinowits G, Yoon C, Thakuria M. Consider Surgery, but Not in This Case. Int J Radiat Oncol Biol Phys. 2018 Jan.100(1):16. Pubmedid: 29254771.
• Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 Feb.8(2):196-215. Pubmedid: 29101162. Pmcid: PMC5809290.
• Park ESY, Rabinowits G, Hamnvik OR, Dagi LR. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J Aapos. 2018 Aug.22(4):310-312. Pubmedid: 29626663.
• Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 Apr.24(7):1546-1553. Pubmedid: 29301825.
• Rabinowits G. Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. Onco Targets Ther. 2017 Sep.10:4803-4807. Pubmedid: 29033592. Pmcid: PMC5628662.
• Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB. Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 Oct.73:160-165. Pubmedid: 28939070.
• Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 Mar.22(3):343-350. Pubmedid: 28209748. Pmcid: PMC5344641.
• Rabinowits G, Barletta J, Sholl LM, Reche E, Lorch J, Goguen L. Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid. 2017 Jan.27(1):125-128. Pubmedid: 27784193.
• Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017 Dec.19(2):129-136. Pubmedid: 28387659.
• Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI. Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017 Aug.7:191. Pubmedid: 28900608. Pmcid: PMC5581802.
• Nambudiri VE, Vivero M, Watson AJ, Thakuria M, Ng A, Russell S, Rabinowits G, LeBoeuf NR. Merkel Cell Carcinoma Presenting as Subcutaneous Breast Masses: An Uncommon Presentation of a Rare Neuroendocrine Neoplasm. Breast J. 2016 Oct.22(1):113-115. Pubmedid: 26607182.
• Sridharan V, Muralidhar V, Margalit DN, Tishler RB, DeCaprio JA, Thakuria M, Rabinowits G, Schoenfeld JD. Merkel Cell Carcinoma: A Population Analysis on Survival. J Natl Compr Canc Ne. 2016 Oct.14(10):1247-1257. Pubmedid: 27697979.
• Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 Jun.22(12):2939-2949. Pubmedid: 26763254.
• Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Brit J Cancer. 2016 Jul.115(2):252-260. Pubmedid: 27380136. Pmcid: PMC4947695.
• Crall C, Morley KW, Rabinowits G, Schmidt B, Dioun Broyles A, Huang JT. Merkel cell carcinoma in a patient with GATA2 deficiency: a novel association with primary immunodeficiency. Br J Dermatol. 2016 Jan.174(1):169-171. Pubmedid: 26252413.
• Ma L, Donohue C, DeNofrio T, Vitale Pedulla L, Haddad RI, Rabinowits G. Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. J Oncol Pract. 2016 Jan.12(1):e77-e82. Pubmedid: 26330532.
• Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 Apr.38 Suppl 1:E1618-E1624. Pubmedid: 26614576.
• Rabinowits G. Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. Cancers (Basel). 2014 May.6(2):1180-1194. Pubmedid: 24840048. Pmcid: PMC4074823.
• Thakuria M, LeBoeuf NR, Rabinowits G. Update on the biology and clinical management of Merkel cell carcinoma. Am Soc Clin Oncol Educ Book. 2014 Jan.e405-e410. Pubmedid: 24857131.
• Chau NG, Rabinowits G, Haddad RI. Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. CURR TREAT OPTION ON. 2014 Dec.15(4):595-610. Pubmedid: 25240410.
• Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar.14(3):257-264. Pubmedid: 23414589.
• Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 2012 Nov.48(11):1085-1089. Pubmedid: 22840785.
• Keung EZ, Liu X, Nuzhad A, Rabinowits G, Patel V. In-hospital and long-term outcomes after percutaneous endoscopic gastrostomy in patients with malignancy. J Am Coll Surg. 2012 Dec.215(6):777-786. Pubmedid: 22999329.
• Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. Am J Med Sci. 2010 Feb.339(2):148-151. Pubmedid: 20087165.
• Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009 Jan.10(1):42-46. Pubmedid: 19289371.
• Rabinowits G, Shuster TD, Pazianos AG, Laber DA. Indolent course of thymic carcinoid. J Clin Oncol. 2007 Mar.25(9):1138-1139. Pubmedid: 17369578.
• Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs. 2003 Sep.14(8):665-668. Pubmedid: 14501391.